These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 29679316)

  • 1. Cost Effectiveness of Human Papillomavirus Vaccination for Men Who have Sex with Men; Reviewing the Available Evidence.
    Setiawan D; Wondimu A; Ong K; van Hoek AJ; Postma MJ
    Pharmacoeconomics; 2018 Aug; 36(8):929-939. PubMed ID: 29679316
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of sex-neutral HPV-vaccination in Sweden, accounting for herd-immunity and sexual behaviour.
    Wolff E; Elfström KM; Haugen Cange H; Larsson S; Englund H; Sparén P; Roth A
    Vaccine; 2018 Aug; 36(34):5160-5165. PubMed ID: 30017146
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-Effectiveness Study of HPV Vaccination as a Primary Prevention Strategy for Anal Cancer in HIV-Positive Men in Chile.
    Vargas Parada C; Lennert Veerman J
    Value Health Reg Issues; 2016 Dec; 11():17-23. PubMed ID: 27986194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Health economic analysis of human papillomavirus vaccines in women of Chile: perspective of the health care payer using a Markov model.
    Gomez JA; Lepetic A; Demarteau N
    BMC Public Health; 2014 Nov; 14():1222. PubMed ID: 25424716
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-Term Outcomes of Adding HPV Vaccine to the Anal Intraepithelial Neoplasia Treatment Regimen in HIV-Positive Men Who Have Sex With Men.
    Deshmukh AA; Chhatwal J; Chiao EY; Nyitray AG; Das P; Cantor SB
    Clin Infect Dis; 2015 Nov; 61(10):1527-35. PubMed ID: 26223993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of precancerous anal intraepithelial lesions in human immunodeficiency virus-positive men who have sex with men: Clinical effectiveness and cost-effectiveness.
    Deshmukh AA; Chiao EY; Cantor SB; Stier EA; Goldstone SE; Nyitray AG; Wilkin T; Wang X; Chhatwal J
    Cancer; 2017 Dec; 123(23):4709-4719. PubMed ID: 28950043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incremental cost-effectiveness evaluation of vaccinating girls against cervical cancer pre- and post-sexual debut in Belgium.
    Demarteau N; Van Kriekinge G; Simon P
    Vaccine; 2013 Aug; 31(37):3962-71. PubMed ID: 23777952
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Perceptions of HPV and attitudes towards HPV vaccination amongst men who have sex with men: A qualitative analysis.
    Nadarzynski T; Smith H; Richardson D; Pollard A; Llewellyn C
    Br J Health Psychol; 2017 May; 22(2):345-361. PubMed ID: 28191723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of human papillomavirus vaccination in low and middle income countries: a systematic review.
    Fesenfeld M; Hutubessy R; Jit M
    Vaccine; 2013 Aug; 31(37):3786-804. PubMed ID: 23830973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An Umbrella Review of the Cost Effectiveness of Human Papillomavirus Vaccines.
    Tran PT; Riaz M; Chen Z; Truong CB; Diaby V
    Clin Drug Investig; 2022 May; 42(5):377-390. PubMed ID: 35488964
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-Effectiveness Analysis of Universal Human Papillomavirus Vaccination Using a Dynamic Bayesian Methodology: The BEST II Study.
    Haeussler K; Marcellusi A; Mennini FS; Favato G; Picardo M; Garganese G; Bononi M; Costa S; Scambia G; Zweifel P; Capone A; Baio G
    Value Health; 2015 Dec; 18(8):956-68. PubMed ID: 26686779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness analysis of human papillomavirus vaccination in South Africa accounting for human immunodeficiency virus prevalence.
    Li X; Stander MP; Van Kriekinge G; Demarteau N
    BMC Infect Dis; 2015 Dec; 15():566. PubMed ID: 26652918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Health economic evaluation of Human Papillomavirus vaccines in women from Venezuela by a lifetime Markov cohort model.
    Bardach AE; Garay OU; Calderón M; Pichón-Riviére A; Augustovski F; Martí SG; Cortiñas P; Gonzalez M; Naranjo LT; Gomez JA; Caporale JE
    BMC Public Health; 2017 Feb; 17(1):152. PubMed ID: 28148228
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of two dose and three dose human papillomavirus vaccine schedules: cost effectiveness analysis based on transmission model.
    Jit M; Brisson M; Laprise JF; Choi YH
    BMJ; 2015 Jan; 350():g7584. PubMed ID: 25567037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of human papillomavirus vaccine in HIV-infected men for the prevention of anal dysplasia and cancer.
    Cachay ER; Mathews WC
    AIDS Rev; 2014; 16(2):90-100. PubMed ID: 24818632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cervical cancer treatment costs and cost-effectiveness analysis of human papillomavirus vaccination in Vietnam: a PRIME modeling study.
    Van Minh H; My NTT; Jit M
    BMC Health Serv Res; 2017 May; 17(1):353. PubMed ID: 28506297
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A cost-utility analysis of cervical cancer screening and human papillomavirus vaccination in the Philippines.
    Guerrero AM; Genuino AJ; Santillan M; Praditsitthikorn N; Chantarastapornchit V; Teerawattananon Y; Alejandria M; Toral JA
    BMC Public Health; 2015 Jul; 15():730. PubMed ID: 26223975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness analysis of introducing universal human papillomavirus vaccination of girls aged 11 years into the National Immunization Program in Brazil.
    Novaes HM; de Soárez PC; Silva GA; Ayres A; Itria A; Rama CH; Sartori AM; Clark AD; Resch S
    Vaccine; 2015 May; 33 Suppl 1():A135-42. PubMed ID: 25919154
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A cost-effectiveness analysis of human papillomavirus vaccination of boys for the prevention of oropharyngeal cancer.
    Graham DM; Isaranuwatchai W; Habbous S; de Oliveira C; Liu G; Siu LL; Hoch JS
    Cancer; 2015 Jun; 121(11):1785-92. PubMed ID: 25867018
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The healthcare costs of treating human papillomavirus-related cancers in Norway.
    Hylin H; Thrane H; Pedersen K; Kristiansen IS; Burger EA
    BMC Cancer; 2019 May; 19(1):426. PubMed ID: 31064346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.